Breast saving operation and adjuvant therapy of breast cancer. Report of the National Institute of Health (NIH) consensus development conference, Washington, D.C., USA, 18-21 June 1990
Kaufmann, M.; Jonat, W.; Eiermann, W.; Maass, H.; Bastert, G.
Onkologie 13(5): 394-396
1990
ISSN/ISBN: 0378-584X PMID: 2101602 Document Number: 239061
Document emailed within 1 workday
Related Documents
Abe, R.; Tsuchiya, A.; Koie, H.; Ono, K.; Abo, S.; Saito, K.; Tsukamoto, M.; Sato, T.; Mori, S.; Motoki, R. 1988: Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(9): 2707-2712Sattin, R W.; Rubin, G L.; Wingo, P A.; Webster, L A.; Ory, H W. 1987: Oral-Contraceptive Use and the Risk of Breast Cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development Obstetric and Gynecologic Survey 42(2): 120-121
Hillman, B.J. 1997: Report of the Department of Defense, National Cancer Institute, Department of Health and Human Services Office of Women's Health workshop on the mobile breast care center Academic Radiology 4(6): 451-457
Giles, K.; Flynn, P.J.; Dalton, R.; Zera, R. 1993: National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial Minnesota Medicine 76(12): 25-27
Lüscher, N.J. 1992: Reconstructive measures in local recurrence after breast saving therapy of breast cancer Helvetica Chirurgica Acta 59(1): 181-187
Von Fournier, D.; Wannenmacher, M.; Hirsch, J. 1992: Josef Hirsch--pioneer of breast saving therapy of breast cancer Zentralblatt für Gynakologie 114(4): 201-203
Stierli, P.; Spichtig, S.; Aeberhard, P. 1992: Breast saving therapy of breast cancer: sensitivity of mammography in relation to primary tumor size Helvetica Chirurgica Acta 59(1): 247-252
Lüscher, N.J.; Tschopp, H.M. 1989: Local late sequelae following breast saving therapy of breast cancer: problem cases and possibilities for their correction Helvetica Chirurgica Acta 55(6): 861-868
1991: NIH consensus conference. Treatment of early-stage breast cancer JAMA 265(3): 391-395
2004: Adjuvant chemotherapy for early breast cancer: protocol and nonprotocol treatment options. Proceedings of a national research leader think tank and 3 regional breast cancer update working group meetings. July-October 2003 Oncology 18(4 Suppl. 1): 5-22
Castiglione-Gertsch, M.; Tattersall, M.; Hacking, A.; Goldhirsch, A.; Gudgeon, A.; Gelber, R.D.; Lindtner, J.; Coates, A.; Collins, J.; Isley, M.; Senn, H.J.; Rudenstam, C.M. 1997: Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group European Journal of Cancer 33(14): 2321-2325
Yip, C-Har.; Cazap, E.; Anderson, B.O.; Bright, K.L.; Caleffi, M.; Cardoso, F.; Elzawawy, A.M.; Harford, J.B.; Krygier, G.D.; Masood, S.; Murillo, R.; Muse, I.M.; Otero, I.V.; Passman, L.J.; Santini, L.A.; da Silva, R.Corrêa.Ferreira.; Thomas, D.B.; Torres, S.; Zheng, Y.; Khaled, H.M. 2011: Breast cancer management in middle-resource countries (MRCs): consensus statement from the Breast Health Global Initiative Breast 20 Suppl. 2: S12-S19
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Yoshida, M.; Saji, S.; Takagi, H.; Takeuchi, S.; Tsuda, H.; Nimura, Y.; Mizumoto, R.; Miyazaki, I.; Kobayashi, S.; Noguchi, M. 1993: A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. the Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(15): 2325-2333
Shtern, F. 1998: Mobile Breast Care Center: a joint program of the Department of Defense, U.S. Public Health Service's Office on Women's Health, and the National Cancer Institute Academic Radiology 5 Suppl. 2: S409-S410
Mitsuyama, S.; Kuroda, Y.; Ohsato, K.; Nakamura, Y.; Murakami, F.; Nishikata, F.; Ikeda, S.; Egami, T.; Mori, A.; Ohe, H. 1996: Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(9): 1153-1160
Santen, R.; Pritchard, K.; Burger, H. 1998: The consensus conference on treatment of estrogen deficiency symptoms in women surviving breast cancer Obstetrical and Gynecological Survey 53(10 Suppl): S1-83
Kitamura, M.; Tominaga, T.; Hayashi, K.; Takahashi, I.; Kosaki, G. 1985: Preliminary report of adjuvant chemo-endocrine therapy for breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 12(1): 111-117
Osaki, A.; Saeki, T. 2007: Future direction of adjuvant chemotherapy for breast cancer following new risk categories of St. Gallen Consensus Nihon Rinsho. Japanese Journal of Clinical Medicine 65 Suppl. 6: 407-413
Ogawa, Y.; Aono, T.; Yamada, T.; Nishikawa, K.; Ikeda, K.; Tokunaga, S.; Okawa, K.; Ikehara, T. 2010: Evaluation of liaison-clinical pathway for patients with breast cancer undergoing adjuvant therapy after curative operation--data from questionnaire survey of 56 clinics and 105 patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(8): 1477-1481